The UK poultry industry has welcomed a landmark trial of new vaccines against highly pathogenic avian influenza (HPAI) in turkeys, marking a pivotal step in tackling bird flu. The trial, launched in March 2026, focuses exclusively on turkeys due to their high susceptibility to the disease and aims to provide science-led solutions to protect flocks and sustain trade.
Background: Bird Flu Challenges in the UK
- Avian influenza (HPAI) has caused severe disruption to both commercial and backyard flocks in recent years.
- Turkeys are particularly vulnerable, with past outbreaks leading to rapid onset of clinical signs and high mortality.
- The British Poultry Council emphasized the need for sustainable, science-led solutions to reduce the strain on producers.
Details of the New Vaccine Trial
- Launch date: Early March 2026.
- Location: England, under the supervision of the Department for Environment, Food & Rural Affairs (DEFRA) and the Animal and Plant Health Agency.
- Focus: Exclusively on turkeys, testing vaccine efficacy in real-world farm conditions.
- Goals:
- Assess how well vaccines protect turkeys against HPAI.
- Explore surveillance strategies to maintain international trade.
- Provide insights into long-term disease management.
Industry Reaction
- Positive reception: UK poultry producers view the trial as a turning point in the fight against bird flu.
- Trade implications: Successful vaccination could help the UK retain export markets by showing effective disease control.
- Scientific importance: The trial is expected to generate valuable data on vaccine performance and monitoring systems.
Why Turkeys?
- Turkeys are more susceptible to HPAI compared to chickens or ducks.
- Outbreaks in turkeys often result in high mortality rates, making them a priority species for vaccine testing.
- Protecting turkeys is critical for both commercial production and food security.
Broader Context
- Across Europe, avian influenza cases have recently declined after a winter peak, but the overall number of outbreaks remains higher than in previous years.
- The UK trial aligns with broader European efforts to strengthen biosecurity and disease prevention.
Key Takeaways
- First targeted turkey vaccine trial in the UK against bird flu.
- Aims to balance animal health, trade sustainability, and biosecurity.
- Seen as a critical step forward by industry leaders and government agencies.
Sources: Available upon request